The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis; Sanofi/Regeneron
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi/Aventis
 
Ana Laura Ortega Granados
No Relationships to Disclose
 
Filippo de Marinis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Takeda
 
Oren Meyers
Employment - GlaxoSmithKline
 
Susan Boklage
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Qin Shen
Employment - Genmab (I); GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline; GlaxoSmithKline (I)
 
Lillian Cho
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline